Ricardo Díez Valle1, Constantinos G Hadjipanayis2, Walter Stummer3. 1. Department of Neurosurgery, University Clinic, Navarra, Spain. rdiezvalle@unav.es. 2. Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Department of Neurosurgery, Universitätsklinikum Münster, Münster, Germany.
Abstract
INTRODUCTION: 5-aminolevulinic acid (5-ALA) was approved by the FDA in June 2017 as an intra-operative optical imaging agent for patients with gliomas (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. 5-ALA fluorescence-guided surgery (FGS) has been in widespread use in Europe and other continents since 2007. METHODS: We reviewed the data available and summarize the most important known uses of 5-ALA FGS and its potential future applications. RESULTS/ CONCLUSIONS: The technique has been extensively studied, and more than 300 papers have been published on this topic. Visualization of high-grade glioma tissue is robust and reproducible, and can impact the extent of tumor resection and patient outcomes. 5-ALA FGS for other kind of tumors needs further development.
INTRODUCTION:5-aminolevulinic acid (5-ALA) was approved by the FDA in June 2017 as an intra-operative optical imaging agent for patients with gliomas (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. 5-ALA fluorescence-guided surgery (FGS) has been in widespread use in Europe and other continents since 2007. METHODS: We reviewed the data available and summarize the most important known uses of 5-ALAFGS and its potential future applications. RESULTS/ CONCLUSIONS: The technique has been extensively studied, and more than 300 papers have been published on this topic. Visualization of high-grade glioma tissue is robust and reproducible, and can impact the extent of tumor resection and patient outcomes. 5-ALAFGS for other kind of tumors needs further development.
Authors: Alba Alfonso-Garcia; Julien Bec; Shamira Sridharan Weaver; Brad Hartl; Jakob Unger; Matthew Bobinski; Mirna Lechpammer; Fady Girgis; James Boggan; Laura Marcu Journal: J Biophotonics Date: 2019-08-09 Impact factor: 3.207
Authors: Loretta Scolaro; Dirk Lorenser; Bryden C Quirk; Rodney W Kirk; Louisa A Ho; Elizabeth Thomas; Jiawen Li; Christobel M Saunders; David D Sampson; Rebecca O Fuller; Robert A McLaughlin Journal: J Biomed Opt Date: 2022-07 Impact factor: 3.758
Authors: Feredun Azari; Gregory Kennedy; Elizabeth Bernstein; Constantinos Hadjipanayis; Alexander Vahrmeijer; Barbara Smith; Eben Rosenthal; Baran Sumer; Jie Tian; Eric Henderson; Amy Lee; Quyen Nguyen; Summer Gibbs; Brian Pogue; Daniel Orringer; Cleopatra Charalampaki; Linda Martin; Janos Tanyi; Major Lee; John Y Lee; Sunil Singhal Journal: J Biomed Opt Date: 2021-05 Impact factor: 3.170
Authors: John Y K Lee; Steve S Cho; Walter Stummer; Janos L Tanyi; Alexander L Vahrmeijer; Eben Rosenthal; Barbara Smith; Eric Henderson; David W Roberts; Amy Lee; Constantinos G Hadjipanayis; Jeffrey N Bruce; Jason G Newman; Sunil Singhal Journal: J Biomed Opt Date: 2019-12 Impact factor: 3.170
Authors: Alba Alfonso-García; Xiangnan Zhou; Julien Bec; Silvia N Anbunesan; Farzad Fereidouni; Lee-Way Jin; Han S Lee; Orin Bloch; Laura Marcu Journal: J Biomed Opt Date: 2022-02 Impact factor: 3.758